🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Revelation Biosciences stock hits 52-week low at $0.7

Published 12/03/2024, 10:42 PM
REVB
-

Revelation Biosciences Inc. (REVB) stock has tumbled to a 52-week low, touching down at $0.7, with a current market capitalization of just $4.08 million. According to InvestingPro analysis, the company's overall financial health score stands at a concerning 1.72, labeled as WEAK. This significant drop reflects a stark contrast to the company's performance over the past year, with a 1-year change showing a precipitous decline of -95.86%. While the stock has shown a strong return of 27% over the last week, InvestingPro data reveals the company is quickly burning through cash, with negative free cash flow. Investors are closely monitoring the biotech firm's trajectory as it navigates through a challenging period marked by this latest low point in its stock price. InvestingPro subscribers have access to 12 additional key insights about REVB's financial outlook.

In other recent news, Revelation Biosciences has received FDA approval for a Phase 1b clinical trial of its drug candidate, Gemini, aimed at treating patients with chronic kidney disease. The study is set to evaluate the safety and efficacy of Gemini, with a primary focus on the tolerability of a single dose in CKD patients. Revelation Biosciences is also confronting potential delisting from the Nasdaq due to noncompliance with the minimum bid price and stockholders' equity requirements, but plans to appeal these notices and request a hearing to maintain its listing status.

Moreover, the company has entered into agreements to exercise Class D Common Stock Warrants for about 2.5 million shares, expecting to generate approximately $3.8 million in gross proceeds. Revelation Biosciences was recently ordered to pay a $7.3 million court judgment to LifeSci Capital LLC, but confirmed it has sufficient cash reserves to meet this judgment without impacting its ongoing programs. The company reported successful results from a Phase 1 clinical trial for Gemini, following which Roth Capital Partners (WA:CPAP) and MKM Partners maintained their Buy rating on Revelation Biosciences. These are the recent developments surrounding the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.